Skip to main content

Advertisement

SpringerLink
Log in

Relative Risk of COVID-19 Reinfection by Demographic and Vaccination Factors During the Period March 2020-October 2022

  • Original Paper
  • Published:
Journal of Community Health Aims and scope Submit manuscript

Abstract

The risk of reinfection has been difficult to quantify throughout the pandemic, making the case for COVID-19 vaccination and receipt of booster doses to the public difficult for the public health community. To address this question, Michigan statewide COVID-19 infection and vaccination data was utilized in this cross-sectional study to determine the risk of reinfection by vaccination status. Cases were divided into subgroups by vaccination status, and the risk of reinfection in the various vaccination categories was then calculated by dividing the cumulative incidence of reinfection in a vaccine category by the cumulative incidence of reinfection of those not in that category Within this population, the risk of becoming reinfected was 1.6 times higher for those who were unvaccinated than those who were vaccinated; those with a primary series saw a 27% reduced risk of reinfections compared to those without a primary series. Those with an additional booster dose had a modest improvement, with 35% reduced risk of reinfection when compared to the other groups combined. These results provide population level data to support current public health vaccination recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arslan, Y., Akgul, F., Sevim, B., Varol, Z. S., & Tekin, S. (2022). Reinfection in COVID-19: Do we exaggerate our worries? European Journal of Clinical Investigation, 52(6), https://doi.org/10.1111/eci.13767.

  2. Bowe, B., Xie, Y., & Al-Aly, Z. (2022). Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine, 28, 2398–2405. https://doi.org/10.1038/s41591-022-02051-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Silk, B. J., Scobie, H. M., Duck, W. M., et al. (2023). COVID-19 Surveillance after Expiration of the Public Health Emergency Declaration ― United States, May 11, 2023. Mmwr. Morbidity and Mortality Weekly Report, 72, 523–528. https://doi.org/10.15585/mmwr.mm7219e1.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Nielsen, K. F., Moustsen-Helms, I. R., Schelde, A. B., Gram, M. A., Emborg, H. D., Nielsen, J. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of alpha, Delta, or Omicron dominance: A Danish nationwide study. 2022 PLoS Med 19(11): e1004037. https://doi.org/10.1371/journal.pmed.1004037.

  5. Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced risk of Reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021. Mmwr. Morbidity and Mortality Weekly Report, 70, 1081–1083. https://doi.org/10.15585/mmwr.mm7032e1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Interim clinical Considerations for Use of COVID-19 Vaccines in the United States (2023, June 14). CDC. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#:~:text=COVID%2D19%20vaccination%20is%20recommended,date%20with%20COVID%2D19%20vaccination.

  7. Thompson, M. G., Natarajan, K., Irving, S. A., et al. (2022). Effectiveness of a third dose of mRNA vaccines against COVID-19–Associated Emergency Department and Urgent Care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance — VISION network, 10 States, August 2021–January 2022. Mmwr. Morbidity and Mortality Weekly Report, 71, 139–145. https://doi.org/10.15585/mmwr.mm7104e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Surie, D., DeCuir, J., Zhu, Y., et al. (2022). Early estimates of Bivalent mRNA vaccine effectiveness in preventing COVID-19–Associated hospitalization among immunocompetent adults aged ≥ 65 years — IVY Network, 18 States, September 8–November 30, 2022. Mmwr. Morbidity and Mortality Weekly Report, 71, 1625–1630. https://doi.org/10.15585/mmwr.mm715152e2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The work was supported by the Centers for Disease Control and Prevention, grant number NU50CK000510-01-14.

Author information

Authors and Affiliations

  1. Michigan Department of Health and Human Services, Lansing, MI, USA

    Enaholo Omoike, Andrea Miceli, Katherine Busen, Alexander Kohrman, Mohit Sharma & Pauline Harrington

Authors
  1. Enaholo Omoike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Miceli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katherine Busen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander Kohrman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohit Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pauline Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Enaholo Omoike.

Ethics declarations

Competing interests

The authors have no competing interests to declare that are relevant to the content of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Omoike, E., Miceli, A., Busen, K. et al. Relative Risk of COVID-19 Reinfection by Demographic and Vaccination Factors During the Period March 2020-October 2022. J Community Health 49, 339–342 (2024). https://doi.org/10.1007/s10900-023-01303-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10900-023-01303-8

Keywords

Search

Navigation